Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Remdesivir. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | KRAS | P01116 | 1/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.32 |
| ▸ | BTN3A1 | O00481 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Remdesivir SCHEMBL31156820 | 1.00 | TMPRSS2 (0.40) | TMPRSS2CYP3A4CYP2C9KRASRIPK1 | |
| Remdesivir SCHEMBL17712238 | 1.00 | TMPRSS2 (0.40) | TMPRSS2CYP3A4CYP2C9KRASRIPK1 | |
| Remdesivir SCHEMBL17712227 | 1.00 | TMPRSS2 (0.40) | TMPRSS2CYP3A4CYP2C9KRASRIPK1 | |
| Remdesivir SCHEMBL22143154 | 1.00 | TMPRSS2 (0.40) | TMPRSS2CYP3A4CYP2C9KRASRIPK1 | |
| Remdesivir SCHEMBL23685886 | 1.00 | TMPRSS2 (0.40) | TMPRSS2CYP3A4CYP2C9KRASRIPK1 | |
| Remdesivir SCHEMBL17712269 | 1.00 | TMPRSS2 (0.40) | TMPRSS2CYP3A4CYP2C9KRASRIPK1 | |
| Remdesivir SCHEMBL24494884 | 1.00 | TMPRSS2 (0.40) | TMPRSS2CYP3A4CYP2C9KRASRIPK1 | |
| Remdesivir SCHEMBL24494885 | 1.00 | TMPRSS2 (0.40) | TMPRSS2CYP3A4CYP2C9KRASRIPK1 | |
| Remdesivir SCHEMBL20500116 | 1.00 | TMPRSS2 (0.40) | TMPRSS2CYP3A4CYP2C9KRASRIPK1 | |
| Remdesivir SCHEMBL30001735 | 1.00 | TMPRSS2 (0.40) | TMPRSS2CYP3A4CYP2C9KRASRIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240024341-A1 | INHALATION FORMULATIONS OF 1`-CYANO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS | GILEAD SCIENCES, INC. | 2024-01-25 | — | — | US | disclosed |
| US-11382926-B2 | Methods for treating Arenaviridae and Coronaviridae virus infections | GILEAD SCIENCES, INC. (US) | 2022-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11382926-B2 | Methods for treating Arenaviridae and Coronaviridae virus infections | ACE, PNP, ACE2 | TMPRSS2 12/4885CYP3A4 1145/4885CYP2C9 2167/4885 |
| US-20240024341-A1 | INHALATION FORMULATIONS OF 1`-CYANO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS | SLC29A1, SLC28A1, RNMT | TMPRSS2 4176/4885CYP3A4 1076/4885CYP2C9 651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.